News

DiNAMIQS strengthens leadership with Kathrin Schneider

Schlieren, Zurich – DiNAMIQS has appointed Kathrin Schneider as its new Head of Business Development for Europe and the Asia-Pacific region (APAC). According to the Schlieren-based life sciences company, she has experience in establishing structures that enable sustainable, long-term growth. DiNAMIQS, based in the Bio-Technopark Schlieren-Zurich, has expanded its management team...

read more

Swiss Biotech Day 2026 – May 3-5, Congress Center Basel, Switzerland

The power of international collaboration Since 2021, the Swiss Biotech Day has seen remarkable growth every year and has become a premier global biotechnology conference for life sciences professionals, fostering international collaboration and impactful partnerships. In 2025 it attracted more than 3,000 participants from 49 countries, including 25 international delegations. It...

read more

InSphero completes acquisition of Doppl

We are pleased to announce that our acquisition of Doppl SA, including the Sun Bioscience technology, has officially been completed. This milestone expands our capabilities in human-relevant 3D biology and strengthens the support we offer across preclinical research. Doppl brings a distinctive organoid technology portfolio featuring tessellated organoid arrays, a leading biobank,...

read more

InSphero has received the Supplier Performance Recognition Award from Scientist.com for the third consecutive year

Unlike typical award programs, this recognition is based entirely on platform performance metrics, reflecting real activity and real outcomes across global R&D teams. Over the past year, scientists requested and completed studies spanning: 🔹 in vitro toxicology 🔹 pharmacology and assay development 🔹 cell culture and characterization All delivered through an on-demand procurement workflow. Performance indicators...

read more

Neurimmune joins ACCESS-AD consortium, an innovative health initiative to accelerate timely and equitable AD diagnosis, treatment and care

Zurich, Switzerland - 13.01.2026 Neurimmune today announced that the company joined the ACCESS-AD consortium, a new European initiative to accelerate the implementation of scientific innovations for Alzheimer’s disease (AD) management in real-world health systems. The international consortium - bringing together academic institutions, industry partners, SMEs and patient organisations - is a five-year...

read more